Abstract:Objectives: Lung injury induced by ischemia-reperfusion is the main cause of early graft failure after lung transplantation, which may result from oxygen-free radicals, inflammatory cytokine production, and polymorphonuclear leukocyte accumulation into the interstitium, resulting in severe lung edema. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) belongs to the nuclear receptor superfamily and has an anti-inflammatory effect by preventing the activation of transcription factors such as nuclear factor-kappaB (NF-kappaB). NF-kappaB regulates the expression of many genes of early response products in the development of acute inflammation. We examined the effects of pioglitazone, a synthetic ligand of PPAR-gamma, against lung ischemia-reperfusion injury in rats. Methods: The left lungs of male Wistar rats were rendered ischemic for 90 min and then reperfused for 2 h. Treated animals received pioglitazone (10 mg/kg) 2 h before induction of ischemia. Lung injury was quantified in terms of lung microvascular permeability (Evans blue dye extravasation), tissue lipid peroxidation (thiobarbituric acid reactive substances), and tissue polymorphonuclear leukocyte accumulation (myeloperoxidase activity). The tissue concentrations of tumor necrosis factor-alpha (TNF-alpha) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) were also measured. Statistical analyses were performed by one-way analysis of variance, followed by Sheffe's multiple comparison test. Results: The lung vascular permeability in pioglitazone-treated animals was reduced by 55% of the increase of Evans blue dye extravasation relative to control animals (P=0.003). The protective effects of pioglitazone treatment were correlated with the reduction by 79% of the increase of thiobarbituric acid reactive substances (P=0.045) and the reduction by 58% of myeloperoxidase activity increase (P<0.001). The production of TNF-alpha was reduced by 63% of the increase (P<0.001) and the reduction of CINC-1 was 45% (P<0.001). Pioglitazone did not affect the lung in the sham animals. Conclusions: Pioglitazone treatment before ischemia attenuated lung ischemia-reperfusion injury in rats. The mechanism of these protective effects involves inhibition of the production of proinflammatory cytokines, polymorphonuclear leukocyte accumulation, and tissue lipid peroxidation, resulting in reduced lung edema.

Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model

Renoprotective Effects of Pirfenidone on Chronic Renal Allograft Dysfunction by Reducing Renal Interstitial Fibrosis in a Rat Model

Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway

Pirfenidone alleviates smoke inhalation lung injury of rats via the NF‐κB signaling pathway

Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina

Pirfenidone treatment reduces cardiac allograft vasculopathy in a mouse model

Pirfenidone in prevention and treatment of radiation pulmonary fibrosis

PIRFENIDONE AMELIORATES LIPOPOLYSACCHARIDE-INDUCED PULMONARYINFLAMMATION AND FIBROSIS BY BLOCKING NLRP3 INFLAMMASOME ACTIVATION

Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model

Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats

Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias

Real-life Experiences in a Single Center: Efficacy of Pirfenidone in Idiopathic Pulmonary Fibrosis and Fibrotic Idiopathic Non-Specific Interstitial Pneumonia Patients

A Protective Effect of Pirfenidone in Lung Fibroblast–Endothelial Cell Network via Inhibition of Rho-Kinase Activity

Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats.

Renoprotective Mechanisms of Pirfenidone in Hypertension-Induced Renal Injury: Through Anti-Fibrotic and Anti-Oxidative Stress Pathways

Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice

Pirfenidone effectively reverses experimental liver fibrosis